Form 8-K - Current report:
SEC Accession No. 0001641172-25-011633
Filing Date
2025-05-20
Accepted
2025-05-20 11:48:02
Documents
15
Period of Report
2025-05-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 46152
2 EX-10.1 ex10-1.htm EX-10.1 68555
  Complete submission text file 0001641172-25-011633.txt   337971

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ptix-20250520.xsd EX-101.SCH 3515
4 XBRL DEFINITION FILE ptix-20250520_def.xml EX-101.DEF 26546
5 XBRL LABEL FILE ptix-20250520_lab.xml EX-101.LAB 36500
6 XBRL PRESENTATION FILE ptix-20250520_pre.xml EX-101.PRE 25170
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5500
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 25967182
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)